Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Neurology

Alzheimer's disease (AD)

EPH receptor A4
(EPHA4); b-amyloid (Ab)

Mouse studies suggest a small molecule EPHA4 inhibitor could help treat AD. In mouse models of AD, greater hippocampal levels of activated Epha4 correlated with AD-associated loss of synaptic functions. In hippocampal slices from normal mice, a peptide inhibitor of EPHA4 decreased Ab-induced loss of neuronal plasticity compared with no treatment. In two mouse models of AD, oral treatment with the blood brain barrier-penetrant small molecule EPHA4 inhibitor rhynchophylline increased neuronal plasticity compared with no treatment. Ongoing studies include additional testing of rhynchophylline and its analogs in mouse models of AD.

SciBX 7(29); doi:10.1038/scibx.2014.869
Published online July 31, 2014

Patented by The Hong Kong University of Science and Technology; available for licensing

Fu, A.K.Y. et al. Proc. Natl. Acad. Sci. USA; published online June 23, 2014;
doi:10.1073/pnas.1405803111
Contact: Nancy Y. Ip, Hong Kong University of Science and Technology, Hong Kong, China
e-mail:
boip@ust.hk